PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 31, 2026SHILAP Revista de lepidopterología0 citationsOpen Access

Dexmedetomidine vs. midazolam-fentanyl for intraoperative analgesia and sedation: a systematic review and meta analysis

View Full Paper
HHHashim Talib HashimUniversity of Al-QadisiyahMKM KhalifaCairo UniversityASAya Ahmed ShimalUniversity of Baghdad

Key Points

  • The aim is to compare the sedative efficacy and safety of dexmedetomidine versus midazolam-fentanyl during surgery.
  • Conducted a meta-analysis of randomized controlled trials (RCTs).
  • Compared dexmedetomidine to midazolam-fentanyl in surgical patients.
  • Evaluated hemodynamic parameters, respiratory safety, and adverse events.
  • Analyzed data using random effects models for significant heterogeneity.
  • Dexmedetomidine significantly lowered mean arterial pressure by −6.42 mmHg.
  • After excluding an outlier, heart rates were reduced by 6.71 bpm with dexmedetomidine.
  • Respiratory rate and oxygen saturation showed no significant differences between groups.
  • Adverse events were similar between dexmedetomidine and midazolam-fentanyl.

Abstract

Background Ongoing research aims to identify the most effective sedative for procedural sedation. This meta-analysis compares dexmedetomidine with midazolam-fentanyl in surgical patients. Methods We conducted a search through MEDLINE, EMBASE and CENTERAL to find randomized controlled trials (RCTs) comparing dexmedetomidine and midazolam-fentanyl. Data on participant characteristics, intervention details, and outcomes were extracted, focusing on intraoperative hemodynamic parameters, respiratory safety, and adverse events. Sedative efficacy and recovery profiles were also evaluated and assessed descriptively across included studies. Data were analyzed using RevMan 5.4, applying random effects models for significant heterogeneity (I 2 50%). Studies with fewer than three data points per group were excluded, and sensitivity analyses were performed. Results We include 4 RCTs with 259 patients. Dexmedetomidine significantly lowered mean arterial pressure (MAP) by −6.42 mmHg (95% CI: −8.24 to −2.21, p 0.001). Initially, heart rate differences were not significant, but after excluding an outlier, dexmedetomidine reduced heart rates by 6.71 bpm (95% CI: −10.74 to −2.68, p = 0.001). Respiratory rate and oxygen saturation showed no significant differences between groups, and adverse events were comparable. Conclusion Dexmedetomidine offers superior blood pressure control compared to midazolam-fentanyl, with similar safety profiles for respiratory parameters. Further research is needed to assess long-term outcomes such as postoperative delirium and residual sedation.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hashim et al. (2026) studied this question.

synapsesocial.com/papers/69cb63c9e6a8c024954b87cchttps://doi.org/10.3389/fpain.2026.1664460
Ask AI
Helpful
Bookmark
Share
View Full Paper